Niacin promotes revascularization and recovery of limb function in diet-induced obese mice with peripheral ischemia

Pharmacology Research and Perspectives

Volumn 4, Issue 3, 2016, Pages 1-14

  Pang, Dominic K T ^a   Nong, Zengxuan ^b   Sutherland, Brian G ^b   Sawyez, Cynthia G ^a,b   Robson, Debra L ^a   Toma, Jelena ^a   Pickering, J Geoffrey ^a,b,c   Borradaile, Nica M ^a  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Inflammation; Lipotoxicity; Metabolic syndrome; Niacin; Peripheral vascular disease

Indexed keywords

NICOTINIC ACID; TRIACYLGLYCEROL;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MOUSE; NONHUMAN; OBESITY; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; TIBIALIS ANTERIOR MUSCLE; WESTERN DIET;

EID: 85026615039     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.233     Document Type: Article

References (66)

1. Assini JM, Mulvihill EE, Sutherland BG, Telford DE, Sawyez CG, Felder SL, et al. (2013). Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr(-)/(-) mice. J Lipid Res 54: 711-724.
2. Biddinger SB, Almind K, Miyazaki M, Kokkotou E, Ntambi JM, Kahn CR (2005). Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes 54: 1314-1323.
3. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. (2011). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255-2267.
4. Bojic LA, Burke AC, Chhoker SS, Telford DE, Sutherland BG, Edwards JY, et al. (2014). Peroxisome proliferator-activated receptor delta agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 34: 52-60.
5. Borradaile NM, Pickering JG (2009). Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. Aging Cell 8: 100-112.
6. Campia U, Tesauro M, Cardillo C (2012). Human obesity and endothelium-dependent responsiveness. Br J Pharmacol 165: 561-573.
7. Chai JT, Digby JE, Choudhury RP (2013a). GPR109A and vascular inflammation. Curr Atheroscler Rep 15: 325.
8. Chai JT, Digby JE, Ruparelia N, Jefferson A, Handa A, Choudhury RP (2013b). Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells. PLoS ONE 8: e62934.
9. Chantler PD, Frisbee JC (2015). Arterial function in cardio-metabolic diseases: from the microcirculation to the large conduits. Prog Cardiovasc Dis 57: 489-496.
10. Chattopadhyay R, Tinnikov A, Dyukova E, Singh NK, Kotla S, Mobley JA, et al. (2015). 12/15-Lipoxygenase-dependent ROS production is required for diet-induced endothelial barrier dysfunction. J Lipid Res 56: 562-577.
11. Cheang WS, Tian XY, Wong WT, Lau CW, Lee SS, Chen ZY, et al. (2014). Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5' adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor delta pathway. Arterioscler Thromb Vasc Biol 34: 830-836.
12. Chen J, Cui X, Zacharek A, Jiang H, Roberts C, Zhang C, et al. (2007). Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol 62: 49-58.
13. Chen J, Cui X, Zacharek A, Ding GL, Shehadah A, Jiang Q, et al. (2009). Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke. J Cereb Blood Flow Metab 29: 911-920.
14. Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, et al. (2007). Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 148: 160-165.
15. Couturier A, Keller J, Most E, Ringseis R, Eder K (2014). Niacin in pharmacological doses alters microRNA expression in skeletal muscle of obese Zucker rats. PLoS ONE 9: e98313.
16. Creider JC, Hegele RA, Joy TR (2012). Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol 8: 517-528.
17. Dagher Z, Ruderman N, Tornheim K, Ido Y (2001). Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells. Circ Res 88: 1276-1282.
18. Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai J, Wamil M, et al. (2012). Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol 32: 669-676.
19. Dokun AO, Chen L, Lanjewar SS, Lye RJ, Annex BH (2014). Glycaemic control improves perfusion recovery and VEGFR2 protein expression in diabetic mice following experimental PAD. Cardiovasc Res 101: 364-372.
20. Eckardt K, Taube A, Eckel J (2011). Obesity-associated insulin resistance in skeletal muscle: role of lipid accumulation and physical inactivity. Rev Endocr Metab Disord 12: 163-172.
21. Emanueli C, Caporali A, Krankel N, Cristofaro B, Van Linthout S, Madeddu P (2007). Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia. Front Biosci 12: 2003-2012.
22. Folker ES, Baylies MK (2013). Nuclear positioning in muscle development and disease. Front Physiol 4: 363.
23. Frontini MJ, Nong Z, Gros R, Drangova M, O'Neil C, Rahman MN, et al. (2011). Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nat Biotechnol 29: 421-427.
24. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML (2009). Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202: 68-75.
25. Gordon ES (1960). Non-esterified fatty acids in the blood of obese and lean subjects. Am J Clin Nutr 8: 740-747.
26. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, et al. (2013). Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes). J Am Coll Cardiol 62: 1580-1584.
27. Haynes R, Jiang L, Hopewell JC, Li J, Chen F, Parish S, et al. (2013). HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34: 1279-1291.
28. Helies-Toussaint C, Gambert S, Roller P, Tricot S, Lacour B, Grynberg A (2006). Lipid metabolism in human endothelial cells. Biochim Biophys Acta 1761: 765-774.
29. Helisch A, Wagner S, Khan N, Drinane M, Wolfram S, Heil M, et al. (2006). Impact of mouse strain differences in innate hindlimb collateral vasculature. Arterioscler Thromb Vasc Biol 26: 520-526.
30. Huang PH, Lin CP, Wang CH, Chiang CH, Tsai HY, Chen JS, et al. (2012). Niacin improves ischemia-induced neovascularization in diabetic mice by enhancement of endothelial progenitor cell functions independent of changes in plasma lipids. Angiogenesis 15: 377-389.
31. Hughes-Large JM, Pang DK, Robson DL, Chan P, Toma J, Borradaile NM (2014). Niacin receptor activation improves human microvascular endothelial cell angiogenic function during lipotoxicity. Atherosclerosis 237: 696-704.
32. Imrie H, Abbas A, Kearney M (2010). Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim Biophys Acta 1801: 320-326.
33. Kaplon RE, Gano LB, Seals DR (2014). Vascular endothelial function and oxidative stress are related to dietary niacin intake among healthy middle-aged and older adults. J Appl Physiol (1985) 116: 156-163.
34. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, et al. (2007). Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 100: 1589-1596.
35. Kim JA, Montagnani M, Chandrasekran S, Quon MJ (2012). Role of lipotoxicity in endothelial dysfunction. Heart Fail Clin 8: 589-607.
36. King AJ (2012). The use of animal models in diabetes research. Br J Pharmacol 166: 877-894.
37. Kito T, Shibata R, Kondo M, Yamamoto T, Suzuki H, Ishii M, et al. (2012). Nifedipine ameliorates ischemia-induced revascularization in diet-induced obese mice. Am J Hypertens 25: 401-406.
38. Kroon T, Kjellstedt A, Thalen P, Gabrielsson J, Oakes ND (2015). Dosing Profile Profoundly Influences Nicotinic Acid's Ability to Improve Metabolic Control in Rats. J Lipid Res 56: 1679-1690.
39. Landazuri N, Joseph G, Guldberg RE, Taylor WR (2012). Growth and regression of vasculature in healthy and diabetic mice after hindlimb ischemia. Am J Physiol Regul Integr Comp Physiol 303: R48-R56.
40. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. (2014). Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371: 203-212.
41. Lavigne PM, Karas RH (2013). The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 61: 440-446.
42. Li Y, Hazarika S, Xie D, Pippen AM, Kontos CD, Annex BH (2007). In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes 56: 656-665.
43. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S (2011). Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 121: 1163-1173.
44. Maloney E, Sweet IR, Hockenbery DM, Pham M, Rizzo NO, Tateya S, et al. (2009). Activation of NF-κB by Palmitate in Endothelial Cells. A Key Role for NADPH Oxidase-Derived Superoxide in Response to TLR4 Activation. Arterioscler Thromb Vasc Biol 29: 1370-1375.
45. Menon RM, Adams MH, Gonzalez MA, Tolbert DS, Leu JH, Cefali EA (2007a). Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. Int J Clin Pharmacol Ther 45: 448-454.
46. Menon RM, Gonzalez MA, Adams MH, Tolbert DS, Leu JH, Cefali EA (2007b). Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J Clin Pharmacol 47: 681-688.
47. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF (2003). Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 100: 1902-1907
48. Ong KL, Barter PJ, Waters DD (2014). Cardiovascular drugs that increase the risk of new-onset diabetes. Am Heart J 167: 421-428.
49. Reagan-Shaw S, Nihal M, Ahmad N (2008). Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
50. Shireman PK (2007). The chemokine system in arteriogenesis and hind limb ischemia. J Vasc Surg 45: A48-A56.
51. Soriguer F, Garcia-Serrano S, Garcia-Almeida JM, Garrido-Sanchez L, Garcia-Arnes J, Tinahones FJ, et al. (2009). Changes in the serum composition of free-fatty acids during an intravenous glucose tolerance test. Obesity 17: 10-15.
52. Symons JD, Abel ED (2013). Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. Rev Endocr Metab Disord 14: 59-68.
53. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, et al. (2003). PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9: 352-355.
54. Tavintharan S, Woon K, Pek LT, Jauhar N, Dong X, Lim SC, et al. (2011). Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus. Atherosclerosis 215: 176-179.
55. Thoenes M, Oguchi A, Nagamia S, Vaccari CS, Hammoud R, Umpierrez GE, et al. (2007). The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract 61: 1942-1948.
56. Tian XY, Wong WT, Xu A, Lu Y, Zhang Y, Wang L, et al. (2012). Uncoupling protein-2 protects endothelial function in diet-induced obese mice. Circ Res 110: 1211-1216.
57. Toral M, Gomez-Guzman M, Jimenez R, Romero M, Zarzuelo MJ, Utrilla MP, et al. (2015). Chronic peroxisome proliferator-activated receptorbeta/delta agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. J Hypertens 33: 1831-1844.
58. Toth PP, Murthy AM, Sidhu MS, Boden WE (2015). Is HPS2-THRIVE the death knell for niacin? J Clin Lipidol 9: 343-350.
59. van der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, Pickering JG (2005). Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 97: 25-34.
60. van der Veer E, Ho C, O'Neil C, Barbosa N, Scott R, Cregan SP, et al. (2007). Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem 282: 10841-10845.
61. Vita JA, Hamburg NM (2010). Does endothelial dysfunction contribute to the clinical status of patients with peripheral arterial disease? Can J Cardiol 26(Suppl A): 45A-50A.
62. Wang CY, Kim HH, Hiroi Y, Sawada N, Salomone S, Benjamin LE, et al. (2009). Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal 2: ra11.
63. Wende AR, Symons JD, Abel ED (2012). Mechanisms of lipotoxicity in the cardiovascular system. Curr Hypertens Rep 14: 517-531.
64. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA (2010). Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol 30: 968-975.
65. Wu BJ, Chen K, Barter PJ, Rye KA (2012). Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation 125: 150-158.
66. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, et al. (2010). Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 30: 1430-1438.